Northwest Therapies Trauma Psilocybin Study Compassionate Use Study (NWTTPS)
Trauma, Nervous System
About this trial
This is an interventional treatment trial for Trauma, Nervous System focused on measuring Trauma, HIV, MS, SARs-Cov-2, Psilocybin, Microdose, Highjacked Nervous System, Cancer, Depression, PTSD
Eligibility Criteria
Inclusion Criteria:
Psychiatrist, LCPC Therapist, Administrator, On Boarding Plant Medicine Specialist.
Informed Consent
Exclusion Criteria:
Cardiovascular Complication
Sites / Locations
- Ross Allison NPI #1437519899 Administrator Of Study
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Plant Medicine On Boarding
Participant
Psychiatrist
On-Boarding Plant Medicine Specialist
The participant will partner with psychiatrist to reduce SSRI's and on-board psilocybin, every M/W/F with a tailored dose of plant medicine psilocybin in the enhanced micro dose levels or 0.15g. to 0.33g with a monthly dose of 1 gram to 1.5 grams. Study Status, Oversight, Study Design, Outcome Measures, Eligibility, and informed consent will all be metrics of this study.
0.15g. thru 0.33g. tailored to participant, then Monthly a 1 time dose of 1gram to 1.5 grams dose of non-synthesized plant medicine psilocybin.
Psychiatrist QC scaling back SSRI's replacing with psilocybin.
The On-Boarding Provider will control dosage of the plant medicine via Telehealth.